Tag: Basic Materials

Research News and Market Data on MGROF

• MustGrow transitions from R&D to commercialization.
• TerraSante^TM biofertility product manufacturing and sales has commenced, with potential initial sales ramp-up in 2025 and 2026.
• Commercialization of TerraMG^TM soil biopesticide is progressing under the Bayer commercial agreement in the EU, Middle East and Africa.
• Registration work for TerraMG^TM soil biopesticide continues in the U.S. and Canada.
• Expiration of exclusive non-commercial agreements.
• Intellectual property portfolio continues to grow.
• Management presentation and Q&A set for Tuesday September 24, 2024.

Saskatoon, Saskatchewan–(Newsfile Corp. – September 23, 2024) – MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”) is pleased to provide its 2024 pipeline update. The Company is a leader in innovative biological nutrition and crop protection solutions from mustard and today announced significant developments in the commercialization of its flagship products, TerraSante^TM and TerraMG^TM, as the Company advances its efforts to transform sustainable agriculture.

TerraSante^TM: Initial Sales and Market Opportunity

MustGrow is pleased to announce that TerraSante^TM is in the initial stages of commercialization, with product registration successfully obtained in key high value crop growing U.S. states, including California, Florida, Arizona, Idaho, Oregon, and Washington. The Company is receiving purchase orders and sales have commenced, marking a major milestone for the Company.

To assist in executing the direct sales and marketing strategy in the U.S., MustGrow engaged the services of two key industry veterans, Tim Lichatowich and Mike Atkins, who have close to six decades of combined experience in the fruit, vegetable and row crop markets.

“We are seeing strong initial interest in TerraSante^TM, particularly in California, where the market demand for a product like MustGrow’s is significant,” said Mike Atkins. Tim Lichatowich, who led multiple grower and industry meetings in California throughout 2024 also commented, “The potential for TerraSante^TM is even greater than we anticipated, with opportunity for multiple applications per year over large acreages.”

Key highlights of TerraSante^TM‘s market progress include:

• Initial Sales: Sales have commenced in the U.S., following registrations in several key fruit & vegetable growing states.

• Potential Market Opportunity: To date, MustGrow’s representatives are in direct contact with production companies covering an estimated 355,000 acres. These acres support multiple crops per year, therefore, there is potential for multiple applications of TerraSante^TM annually. Sales volume from multiple applications is beyond what was initially anticipated, and as such, the 355,000 acres could potentially translate into 850,000 to 1 million acres per year application potential. This is just on a small fraction of the estimated 5.6 million acres of high value crops in the US (fruit & vegetable; tree, nut & vine; root & tuber).
• Potential Future Growth: For 2024 and 2025, initial sales and successful customer testing results will drive sales growth. Commercial sales and data on product performance is expected during the upcoming winter and spring. From there, management anticipates a full-scale sales ramp-up in 2025 and 2026.

TerraSante^TM Production Update

Manufacture of TerraSante^TM started in 2023 with MustGrow’s first commercial production run. MustGrow is actively planning for larger-scale production to meet anticipated demand. The Company is exploring various production options, including existing and expanded contract manufacturing partnerships.

“This is a very exciting time for MustGrow with actual production and sales,” said Corey Giasson, MustGrow’s President & CEO. “A few years ago, I mentioned that MustGrow was going to start the commercialization process. Well we did, and what you are witnessing is the transformation of the Company from being strictly an R&D company to now one with product sales. Our goal with TerraSante^TM, and other future registered products such as TerraMG^TM, is to not only produce enough product to meet demand but do so in a cost-effective manner so as to increase margins and return on investment. You can be rest assured, that MustGrow’s management focuses on this each and every day.”

TerraSante^TM for Soil and Ecological Health

MustGrow’s soil amendment and biofertility development programs focus on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer’s most valuable asset, and MustGrow’s mustard plant-based technologies are being developed with the intention to improve not only the health of the soil, but also the surrounding ecological environment.

As an organic biofertilizer in wettable powder form, TerraSante^TM contains nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSante^TM has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing.

TerraMG^TM: Progress with Bayer

TerraMG^TM‘s commercialization is progressing under MustGrow’s commercial agreement with Bayer for Europe, the Middle East, and Africa. While registrations are still in process in the US and Canada, MustGrow is encouraged by the ongoing work and progress being made alongside Bayer in the EU.

“We are very pleased with how things are proceeding with Bayer and they have been a great partner,” said MustGrow’s CEO. “Field trials are continuing in multiple countries and regions, and Bayer’s technical, regulatory, production, sales and marketing teams are providing excellent support as we work to advance TerraMG^TM under the commercial agreement.”

Key developments for TerraMG^TM under the Bayer commercial agreement include:

• Signing of the Bayer Commercial Agreement: This agreement, signed in December 2023, includes licensing for Europe, the Middle East, and Africa, and included an upfront payment as well as milestone payments to MustGrow for development and registration work.
• Field Trials and Technical Success with Bayer: Field trials and technical evaluations continue to yield positive results for both nematode and disease treatment, with the next program review scheduled for the end of October at the Annual Biocontrol Industry Meeting (“ABIM”) meeting in Basel.
• Assessing Future Production for Bayer: MustGrow and Bayer are also focusing on sourcing raw materials and scaling production capabilities for future sales and growth.

TerraMG^TM in U.S. and Canada

TerraMG^TM registration work continues to progress in the U.S. with the Environmental Protection Agency (“EPA”) and in Canada with the Pest Management Regulatory Agency (“PMRA”). MustGrow continues to work closely with regulatory agencies and consultants and management remains committed to continuing these registrations.

Exclusive Non-Commercial Agreements

MustGrow is announcing expiration of the exclusive non-commercial agreements with NexusBioAg, Janssen PMP and Sumitomo Corporation. The Company collected substantial data and market analysis through these agreements and will now move forward on a non-exclusive basis with multiple parties to commercialize these opportunities.

Intellectual Property Portfolio

MustGrow continues to build its intellectual property portfolio, with 112 issued and pending patents, even as the Company pivots from R&D toward commercialization. This is up from 84 total patents issued and pending in March of 2023.

The intellectual property pipeline continues to grow through MustGrow’s own work as well as collaborations with university, government and other research groups. Expanded infield applications of existing formulations as well as new active ingredients are generating new product and patent opportunities. Most recently, the Company and Agriculture and Agri-Food Canada announced funding to explore the possibilities of MustGrow’s mustard extracts in the human and animal health area.

Future Roadmap

Looking ahead, MustGrow’s 2024-2025 roadmap focuses on delivering the commercialization of TerraSante^TM and TerraMG^TM, validating product efficacy through sales, and driving global expansion. The Company is committed to fostering its partnership with Bayer and securing new commercial partners in non-commercialized territories, including Mexico, South America, and Asia.

“We are evolving as a Company, and sales, margins and return on investment will become key drivers for our growth moving forward,” said Mr. Giasson. “While blue-sky opportunities remain important, our focus will shift towards delivering on our commercial potential.”

Management Presentation and Q&A

MustGrow is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research. The Company’s CEO Corey Giasson and COO Colin Bletsky will be presenting an update and taking any questions for the audience. The webinar will be a live, interactive online event where attendees are invited to ask the Company questions in real-time following the interview. An archived webcast will be made available for those who cannot join the event live on the day of the webinar.

• Event: Radius Research Pitch, Deep Dive, and Q&A with MustGrow Biologics (MGRO)
• Presentation date & time: Tuesday, September 24th @ 4 PM ET
• Registration link:

Market Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional level discussion and Q&A. Market Radius is hosted by Martin Gagel, former top-ranked technology analyst. By registering for this webinar, you agree to receive email communications from Market Radius Capital, Inc. and from the presenting company (with unsubscribe). Your email will not be further shared. Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice and may own shares in mentioned companies and may be compensated for these services. Content is for information purposes only and is not advice or recommendations and may include incomplete or incorrect information. Investing entails a high degree of risk. This is a production of Market Radius Capital, Inc.

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. The Company has a registered and organically certified biofertility product call TerraSante^TM in key U.S.-states including California. Registrations of TerraSante^TM are owned by MustGrow and production and sales of TerraSante^TM has commenced with ramp-up slated to begin in 2025 and 2026. Commercialization is also occurring under biocontrol, with Bayer signing on under a Commercial Licensing agreement in December 2023 for the TerraMG^TM soil biopesticide in Europe, the Middle East and Africa. MustGrow estimates that Bayer will spend US$35-40 million for upfront and milestone payments and registration work of TerraMG^TM in their respective territory. The Company’s main focus is continued commercialization globally of it products and technologies, and to expand its intellectual property portfolio from approximately 112 patents that are issued and pending. MustGrow is a public company (TSXV: MGRO) and has approximately 51.6 million basic common shares issued and outstanding and 55.7 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: its commercialization strategy; its continuing efforts towards further state-level registrations; TerraSante^TM ability to improve beneficial microbial activity; the ability of TerraSante^TM to increase plant vigor and yields; and the ability of TerraSante^TM to improve crop nutrient uptake. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include market receptivity to investor relations activities as well as those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2024 MustGrow Biologics Corp. All rights reserved.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224296

Research News and Market Data on MGROF

• MustGrow will be receiving funding from Agriculture and Agri-Food Canada to investigate mustard-derived ingredient opportunities in human & animal health applications.
• Potential product opportunities may include application in functional foods and nutraceuticals for improved immunity and gut health in humans, as natural food preservatives, as well as a replacement for antibiotics in animal feeds.

SASKATOON, Saskatchewan, Canada, September 17, 2024 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow“) is pleased to announce funding from Agriculture and Agri-Food Canada (“AAFC“) to investigate mustard-derived ingredient opportunities in human & animal health and food applications (the “Project“). The funding is provided through the AgriScience Program – Projects Component, under the Sustainable Canadian Agricultural Partnership.

The work will be conducted in connection with AAFC’s Guelph Research & Development Centre (“GRDC“) located in Guelph, Ontario, Canada, and it will be led by Dr. Rong Cao. Costs associated with the Project will be covered by both MustGrow and AAFC through a Collaborative Research and Development Agreement under the AgriScience Program. All investigational research activities will be conducted at the GRDC. The funding amount received from AAFC is subject to the negotiation of the Collaborative Research and Development Agreement. The funding does not imply Government of Canada endorsement of MustGrow’s findings, products, or practices.

MustGrow has always suspected potential product ingredient opportunities of mustard derivatives in human & animal health applications, including functional foods and nutraceuticals for improved immunity and gut health in humans, as natural food preservatives, as well as a replacement for antibiotics in animal feeds. The GRDC is a leading research institute in food health attributes and safety.

MustGrow will continue to focus on its core business in natural agricultural biopesticides, biofumigants, and biofertility products derived from the mustard seed or its processing by-products, while pursuing this opportunity in human and animal health in a cost-effective and expedient structure. MustGrow’s biofertility product, TerraSante^TM, is currently being marketed and sold in the United States, with additional biocontrol development programs underway with four global partners: Bayer, Sumitomo Corporation, Janssen PMP, and NexusBioAg.

The Health Program

Together, MustGrow and AAFC will:

• Analyze the major bioactive components in mustard seed that may have antibiotic and gut health applications in both humans and animals.
• Assess yellow mustard extracts for efficacy in converting glucosinolates into active ingredients that may have antibiotic and gut health applications in both humans and animals.
• Test the selected bioactive components for antifungal and antibacterial activities against food spoilage microbes and disease pathogens, including the banana-plaguing disease Fusarium wilt TR4.
• Test the selected bioactive components for antioxidant and anti-inflammatory effects, for use as ingredients in functional foods and nutraceuticals for improved immunity and gut health in both humans and animals.

MustGrow has always believed that there is a potential for new products to be developed and deployed in antibiotic and gut health applications using bioactives derived from the mustard seed. These new applications would be directed at antimicrobial, antioxidant, and anti-inflammatory uses in functional foods, gut health, and nutraceuticals in both human and animal health.

Global Threat

Antimicrobial resistance (“AMR“) has become a leading global cause of death and is one of the greatest global health challenges: a growing threat to both human and animal health, as well as global food security.⁽¹⁾ In 2019, an estimated 4.95 million deaths were associated with bacterial AMR, including 1.27 million deaths directly attributable to bacterial AMR itself.⁽²⁾

The 2022 global animal antibiotics market was valued at US$5.6 billion, with usage estimates for cattle, sheep, chicken, and pigs expected to increase to 107,472 tonnes by 2030 (an 8% increase over 2020).⁽³⁾⁽⁴⁾ Experts warn that overuse of antibiotics in livestock could lead to potentially fatal antibiotic-resistant infections in these animals, and alarmingly in humans as well, as new bacteria emerge with built-in resistance to the human immune system.⁽⁴⁾

Some estimate antibiotic-resistant infections will kill as many as 10 million per year people by 2050 – on par with the 2020 global death toll from all cancers.⁽⁵⁾

Sources:

1. https://www.woah.org/en/what-we-do/global-initiatives/antimicrobial-resistance/
2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis – The Lancet
3. https://www.factmr.com/report/1049/animal-antibiotics-market#:~:text=market%20at%20present%3F-,The%20global%20animal%20antibiotics%20market%20at%20present%20is%20valued%20at,Billion%20in%20the%20year%202022
4. https://www.statista.com/chart/30078/biggest-users-of-antimicrobials-in-food-processing-animals/
5. Chart: Deaths From Drug-Resistant Infections Set To Skyrocket | Statista

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. MustGrow and its leading global partners — Bayer, Janssen PMP (pharmaceutical division of Johnson & Johnson), Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Bayer has a commercial agreement to develop and commercialize MustGrow’s biocontrol soil applications in Europe, Africa, and the Middle East. Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its Organic Materials Review Institute (OMRI Listed^®) and California’s Organic Input Material (OIM) Program registered biofertility product, TerraSante^TM, in key U.S. states including California. Over 150 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection and yield enhancements. Pending regulatory approval, MustGrow’s patented liquid technologies could be applied through injection, standard drip or spray equipment, improving functionality and performance features. MustGrow has approximately 51.6 million basic common shares issued and outstanding and 55.7 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson

Director & CEO

Phone: +1-306-668-2652

info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: the product ingredient opportunities of mustard derivatives in human & animal health application, the use of the proceeds of the funding; the outcome of the Health Program; the continued persistence of antimicrobial resistance; and the Company’s focus on its core products and business. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. These risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Disclaimer:

This news release may include references to third-party information, opinions, or statements. The Company does not guarantee the accuracy, reliability, or completeness of any information provided by third parties. Such information is included solely for informational purposes and should not be construed as endorsements or representations. Readers are advised to independently verify any claims, statements, or conclusions drawn from third-party sources before making any decisions or taking action based on this information.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release. © 2024 MustGrow Biologics Corp. All rights reserved.

Research News and Market Data on MGROF

• MustGrow has received approval from the Florida Department of Agriculture and Consumer Services to commence sales of TerraSante^TM, an organic biofertility product, in the State of Florida.
• Mustard-derived TerraSante^TM focuses on soil and soil microbiome health, nutrient/water use efficiencies, and plant yields.

SASKATOON, Saskatchewan, Canada, September 11, 2024 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”) is pleased to announce receipt of the Florida Department of Agriculture and Consumer Services registration approval for its mustard plant-based TerraSante^TM, an organic biofertility product. The Florida organic certification is included under MustGrow’s existing Organic OMRI Listed^® certifications in Arizona, Idaho, Oregon, and Washington State.

MustGrow’s Florida registration and organic certification is a key pillar in the commercialization strategy with BioAg Product Strategies. In addition to Florida, and recently-awarded Arizona, Idaho, California, Oregon, and Washington State, MustGrow expects to continue its efforts towards further state-level registrations in other pertinent U.S. states.

Florida has approximately 47,300 farms, citrus groves, and ranches totalling 9.7 million acres, producing a wide variety of fruits, vegetables, and floriculture. In 2022, Florida ranked first in the U.S. in the production value of bell peppers (US$262 million), floriculture (US$1.16 billion), foliage plants for indoor use (US$481 million), Valencia oranges (US$289 million), grapefruit (US$706 million), sugarcane (US$752 million), fresh market tomatoes (US$323 million) and watermelons (US$216 million). Florida ranked second in the U.S. in production value for all oranges (US$491 million), strawberries (US$511 million), and sweet corn (US$124 million).⁽¹⁾

TerraSante^TM for Soil and Ecological Health

MustGrow’s soil amendment and biofertility development programs focus on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer’s most valuable asset, and MustGrow’s mustard plant-based technologies are being developed with the intention to improve not only the health of the soil, but also the surrounding ecological environment.

As an organic biofertilizer in soluble mixable form, TerraSante^TM contains nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSante^TM has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing.

To learn more about TerraSante^TM, visit www.mustgrow.ca.

Source:
1) Florida Agriculture Overview and Statistics / Agriculture Industry / Home – Florida Department of Agriculture & Consumer Services (fdacs.gov)

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world.  MustGrow and its leading global partners — Bayer, Janssen PMP (pharmaceutical division of Johnson & Johnson), Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Bayer has a commercial agreement to develop and commercialize MustGrow’s biocontrol soil applications in Europe, Africa, and the Middle East.  Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its Organic Materials Review Institute (OMRI Listed^®) and California’s Organic Input Material (OIM) Program registered biofertility product, TerraSante^TM, in key U.S. states including California.  Over 150 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection and yield enhancements.  Pending regulatory approval, MustGrow’s patented liquid technologies could be applied through injection, standard drip or spray equipment, improving functionality and performance features.  MustGrow has approximately 51.6 million basic common shares issued and outstanding and 55.7 million shares fully diluted.  For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.  Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: its commercialization strategy; its continuing efforts towards further state-level registrations; TerraSante^TM ability to improve beneficial microbial activity; the ability of TerraSante^TM to increase plant vigor and yields; and the ability of TerraSante^TM to improve crop nutrient uptake. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include market receptivity to investor relations activities as well as those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca.  Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release. © 2024 MustGrow Biologics Corp. All rights reserved.

Research News and Market Data on MGROF

• MustGrow has received the Arizona Department of Agriculture approval to commence sales of TerraSante^TM, an organic biofertility product, in the State of Arizona.
• Mustard-derived TerraSante^TM focuses on soil and soil microbiome health, nutrient/water use efficiencies, and plant yields.

SASKATOON, Saskatchewan, Canada, August 22, 2024 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”) is pleased to announce receipt of the Arizona Department of Agriculture registration approval for its mustard plant-based TerraSante^TM, an organic biofertility product. The Arizona organic certification is included under MustGrow’s existing Organic OMRI Listed^® certifications in Idaho, Oregon, and Washington State.

MustGrow’s Arizona registration and organic certification is a key pillar in the commercialization strategy with BioAg Product Strategies. Notably, several large California agriculture companies utilize Arizona’s winter climate for winter farming production. In addition to Arizona, and recently-awarded Idaho, California, Oregon and Washington State, MustGrow expects to continue its efforts towards further state-level registrations in other pertinent U.S. states.

With over 25 million acres of farmland, Arizona farms produced US$3.0 billion in agricultural crop products in 2022.¹ The Vegetable/Melon/Potatoes category led with US$1.43 billion in sales.² Arizona is ranked 2nd in the U.S. production for head lettuce, leaf lettuce, romaine lettuce, cauliflower, broccoli, spinach, and cantaloupe. Yuma County is considered the winter lettuce capital of the world, also highly regarded for its leafy greens, broccoli, and cauliflower.³

TerraSante^TM for Soil and Ecological Health

MustGrow’s soil amendment and biofertility development programs focus on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer’s most valuable asset, and MustGrow’s mustard plant-based technologies are being developed with the intention to improve not only the health of the soil, but also the surrounding ecological environment.

As an organic biofertilizer in soluble mixable form, TerraSante^TM contains nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSante^TM has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing.

To learn more about TerraSante^TM, visit www.mustgrow.ca

Sources:
1. https://farmflavor.com/arizona/arizona-crops-livestock/top-arizona-agriculture-facts/
2. https://www.azfb.org/Article/Arizona-Results-from-the-2022-Census-of-Agriculture
3. https://blog.aghires.com/arizona-ag-facts/

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. MustGrow and its leading global partners — Bayer, Janssen PMP (pharmaceutical division of Johnson & Johnson), Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Bayer has a commercial agreement to develop and commercialize MustGrow’s biocontrol soil applications in Europe, Africa, and the Middle East.  Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its Organic Materials Review Institute (OMRI Listed^®) and California’s Organic Input Material (OIM) Program registered biofertility product, TerraSante^TM, in key U.S. states including California. Over 150 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection and yield enhancements. Pending regulatory approval, MustGrow’s patented liquid technologies could be applied through injection, standard drip or spray equipment, improving functionality and performance features. MustGrow has approximately 51.6 million basic common shares issued and outstanding and 54.1 million shares fully diluted.  For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: its commercialization strategy; its continuing efforts towards further state-level registrations; TerraSante^TM ability to improve beneficial microbial activity; the ability of TerraSante^TM to increase plant vigor and yields; and the ability of TerraSante^TM to improve crop nutrient uptake. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include market receptivity to investor relations activities as well as those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release. © 2024 MustGrow Biologics Corp. All rights reserved.

Research News and Market Data on MGROF

• MustGrow has received the Idaho State Department of Agriculture approval to commence sales of TerraSante^TM, an organic biofertility product, in Idaho.
• Mustard-derived TerraSante^TM focuses on  soil and soil microbiome health, nutrient/water use efficiencies, and plant yields.

SASKATOON, Saskatchewan, Canada, July 31, 2024 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”) is pleased to announce receipt of the Idaho State Department of Agriculture registration approval for its mustard plant-based TerraSante^TM, an organic biofertility product.  The Idaho organic certification is included under MustGrow’s existing Organic OMRI Listed^® certifications in Oregon and Washington State.

Potatoes are Idaho’s top crop with a total value of production of US$1.3 billion in 2023, up from US$1.2 billion in 2022.  Idaho had 330,000 potato acres in 2023, up 12% from 2022.⁽¹⁾

Idaho ranked #1 in the U.S. in five different agriculture commodities in 2021: potatoes, barley, alfalfa hay, peppermint oil and food trout. The state also ranked #2 in the U.S. in 2021 in sugar beets and hops; #4 in dry onions, spring wheat, and lentils, and #5 in dry edible beans, corn silage, and dry edible peas. According to USDA’s National Agricultural Statistics Service, Idaho’s total agricultural crop production in 2021 was US$3.3 billion. Prior to 2021, the total value of Idaho agriculture production had increased for four consecutive years.⁽²⁾

TerraSante^TM for Soil and Ecological Health

MustGrow’s soil amendment and biofertility development programs focus on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields.  Soil is a farmer’s most valuable asset, and MustGrow’s mustard plant-based technologies are being developed with the intention to improve not only the health of the soil, but also the surrounding ecological environment.

As an organic biofertilizer in soluble mixable form, TerraSante^TM contains nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSante^TM has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing.

To learn more about TerraSante^TM, visit www.mustgrow.ca.

In May 2024, MustGrow announced receipt of the California Department of Food Agriculture registration approval for its organic biofertility product TerraSante^TM, and also organic certification from California’s Organic Input Material (OIM) Program, a specific California requirement beyond MustGrow’s existing Organic OMRI Listed^® certifications in Oregon and Washington State. MustGrow’s California registration and organic certification is a key pillar in the commercialization strategy with BioAg Product Strategies.  In addition to Idaho, and recently-awarded California, Oregon and Washington State, MustGrow expects to continue its efforts towards further state-level registrations in other pertinent U.S. states.

Sources:
(1) https://www.uidaho.edu/-/media/UIdaho-Responsive/Files/Extension/publications/reports/financialcondition2023.pdf?la=en#:~:text=Hay%2C%20silage%2C%20feed%20grains%2C,as%20feed%20for%20Idaho%20livestock.&text=2023%2C%20livestock%20cash%20receipts%20are,by%20more%20than%20%241.6%20billion.&text=from%202022’s%20record%20high%20of%20%244.2%20billion.&text=estimated%20at%20%24153%20million%2C%20a%20decrease%20of%2022%25%20from%202022.
(2) Idaho ranks No. 1 in five ag commodities | Idaho Farm Bureau (idahofb.org)

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world.  MustGrow and its leading global partners — Bayer, Janssen PMP (pharmaceutical division of Johnson & Johnson), Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation.  Bayer has a commercial agreement to develop and commercialize MustGrow’s biocontrol soil applications in Europe, Africa, and the Middle East.  Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its Organic Materials Review Institute (OMRI Listed^®) and California’s Organic Input Material (OIM) Program registered biofertility product, TerraSante^TM, in key U.S. states including California.  Over 150 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection and yield enhancements.  Pending regulatory approval, MustGrow’s patented liquid technologies could be applied through injection, standard drip or spray equipment, improving functionality and performance features.  MustGrow has approximately 51.6 million basic common shares issued and outstanding and 54.1 million shares fully diluted.  For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.  Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: the size of the market opportunity, the outcome of the Company’s promotional activities, whether MustGrow’s organic biofertility product will complement the Company’s existing biocontrol programs in preplant soil fumigation, postharvest food preservation, and bioherbicide; the application of MustGrow’s biofungicide, and the efficacy of MustGrow’s technology.  Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.   as well as those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com.  Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2024 MustGrow Biologics Corp. All rights reserved.